MICHAEL TSOVKO: Open Payments
NPI 1447933502 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,026 in 171 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $2,084 · 2025 $3,026
Food & beverage: $2,915Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 20 | $445 |
| ABBVIE INC. | 21 | $410 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $400 |
| Neurocrine BioSciences, Inc. | 11 | $290 |
| E.R. Squibb & Sons, L.L.C. | 34 | $253 |
| Vanda Pharmaceuticals Inc. | 8 | $217 |
| Otsuka America Pharmaceutical, Inc. | 13 | $212 |
| Alkermes, Inc. | 5 | $203 |
| Lundbeck LLC | 9 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $153 |
Products named: VRAYLAR, CAPLYTA, REXULTI, AUSTEDO XR, INGREZZA, COBENFY, FANAPT, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
